DÃ©sirÃ©e E Larenas-Linnemann

List of Publications by Year
in descending order

143 papers	15,020 citations	41344 49 h-index	18647 119 g-index
168 all docs	168 docs citations	168 times ranked	9644 citing authors

#	Article	IF	Citations
1	Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*. Allergy: European Journal of Allergy and Clinical Immunology, 2008, 63, 8-160.	5.7	3,827
2	Allergic Rhinitis and its Impact on Asthma (ARIA) guidelinesâ€”2016 revision. Journal of Allergy and Clinical Immunology, 2017, 140, 950-958.	2.9	1,199
3	The EAACI/GAÂ²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 1393-1414.	5.7	1,008
4	Allergic Rhinitis and its Impact on Asthma (ARIA): Achievements in 10 years and future needs. Journal of Allergy and Clinical Immunology, 2012, 130, 1049-1062.	2.9	486
5	EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 765-798.	5.7	473
6	Speaking the same language: The World Allergy Organization Subcutaneous Immunotherapy Systemic Reaction Grading System. Journal of Allergy and Clinical Immunology, 2010, 125, 569-574.e7.	2.9	406
7	Sublingual immunotherapy: World Allergy Organization position paper 2013 update. World Allergy Organization Journal, 2014, 7, 6.	3.5	395
8	The international EAACI/GAÂ²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 734-766.	5.7	392
9	Sublingual immunotherapy: A comprehensive review. Journal of Allergy and Clinical Immunology, 2006, 117, 1021-1035.	2.9	371
10	Subâ€lingual Immunotherapy: World Allergy Organization Position Paper 2009. Allergy: European Journal of Allergy and Clinical Immunology, 2009, 64, 1-59.	5.7	316
11	International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis. International Forum of Allergy and Rhinology, 2018, 8, 108-352.	2.8	273
12	Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. Journal of Allergy and Clinical Immunology, 2020, 145, 70-80.e3.	2.9	272
13	Allergen immunotherapy for allergic rhinoconjunctivitis: A systematic review and metaâ€analysis. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 1597-1631.	5.7	233
14	EAACI guidelines on allergen immunotherapy: Prevention of allergy. Pediatric Allergy and Immunology, 2017, 28, 728-745.	2.6	171
15	MACVIA-ARIA Sentinel NetworK for allergic rhinitis (MASK-rhinitis): the new generation guideline implementation. Allergy: European Journal of Allergy and Clinical Immunology, 2015, 70, 1372-1392.	5.7	160
16	Exposure and Health Effects of Fungi on Humans. Journal of Allergy and Clinical Immunology: in Practice, 2016, 4, 396-404.	3.8	157
17	Allergen immunotherapy for the prevention of allergy: A systematic review and metaâ€analysis. Pediatric Allergy and Immunology, 2017, 28, 18-29.	2.6	155
18	Grading local side effects of sublingual immunotherapy forÂrespiratory allergy: Speaking the same language. Journal of Allergy and Clinical Immunology, 2013, 132, 93-98.	2.9	144

#	Article	IF	Citations
19	2019 ARIA Care pathways for allergen immunotherapy. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 2087-2102.	5.7	140
20	Treatment of seasonal allergic rhinitis. Annals of Allergy, Asthma and Immunology, 2017, 119, 489-511.e41.	1.0	133
21	Environmental assessment and exposure control of dust mites: a practice parameter. Annals of Allergy, Asthma and Immunology, 2013, 111, 465-507.	1.0	128
22	MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis. Journal of Allergy and Clinical Immunology, 2016, 138, 367-374.e2.	2.9	128
23	å›½é™…è¿‡æ•ä¸é¼»ç‚Žå¦ å…±è¯†å£°æ˜Ž : å¯å°”æ€§é¼»ç‚Ž. International Forum of Allergy and Rhinology, 2018, 8, 108-352.	3.8	124
24	ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle. Clinical and Translational Allergy, 2016, 6, 47.	3.2	121
25	Intranasal corticosteroids in allergic rhinitis in COVIDâ€19 infected patients: An ARIAâ€EAACI statement. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 2440-2444.	5.7	114
26	Urticaria: Collegium Internationale Allergologicum (CIA) Update 2020. International Archives of Allergy and Immunology, 2020, 181, 321-333.	2.1	108
27	MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence. Clinical and Translational Allergy, 2018, 8, 45.	3.2	104
28	Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology. Journal of Allergy and Clinical Immunology, 2019, 143, 864-879.	2.9	103
29	Mobile technology offers novel insights into the control and treatment of allergic rhinitis: The MASK study. Journal of Allergy and Clinical Immunology, 2019, 144, 135-143.e6.	2.9	101
30	Is diet partly responsible for differences in COVID-19 death rates between and within countries?. Clinical and Translational Allergy, 2020, 10, 16.	3.2	97
31	Treatment of allergic rhinitis using mobile technology with realâ€world data: The <scp>MASK</scp> observational pilot study. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 1763-1774.	5.7	94
32	European allergen extract units and potency: review of available information. Annals of Allergy, Asthma and Immunology, 2008, 100, 137-145.	1.0	93
33	Next-generation ARIA care pathways for rhinitis and asthma: a model for multimorbid chronic diseases. Clinical and Translational Allergy, 2019, 9, 44.	3.2	87
34	Handling of allergen immunotherapy in the COVIDâ€19 pandemic: An ARIAâ€EAACI statement. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 1546-1554.	5.7	87
35	Development and implementation of guidelines in allergic rhinitis â€“ an ARIAâ€GA²LEN paper. Allergy: European Journal of Allergy and Clinical Immunology, 2010, 65, 1212-1221.	5.7	85
36	Allergen exposure chambers: harmonizing current concepts and projecting the needs for the future â€“ an <scp>EAACI</scp> Position Paper. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 1035-1042.	5.7	85

#	Article	IF	Citations
37	Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma. Clinical and Translational Allergy, 2019, 9, 16.	3.2	81
38	Taxonomy of Allergenic Fungi. Journal of Allergy and Clinical Immunology: in Practice, 2016, 4, 375-385.e1.	3.8	80
39	COVIDâ€19 pandemic: Practical considerations on the organization of an allergy clinicâ€"An EAACI/ARIA Position Paper. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 648-676.	5.7	79
40	The Allergic Rhinitis and its Impact on Asthma (ARIA) score of allergic rhinitis using mobile technology correlates with quality of life: The MASK study. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 505-510.	5.7	77
41	Adherence to treatment in allergic rhinitis using mobile technology. The <scp>MASK</scp> Study. Clinical and Experimental Allergy, 2019, 49, 442-460.	2.9	73
42	Allergen immunotherapy on the way to product-based evaluationâ€"a WAO statement. World Allergy Organization Journal, 2015, 8, 29.	3.5	70
43	ARIA guideline 2019: treatment of allergic rhinitis in the German health system. Allergologie Select, 2019, 3, 22-50.	3.1	70
44	Work productivity in rhinitis using cell phones: The <scp>MASK</scp> pilot study. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 1475-1484.	5.7	69
45	Daily allergic multimorbidity in rhinitis using mobile technology: A novel concept of the <scp>MASK</scp> study. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 1622-1631.	5.7	69
46	Electronic Clinical Decision Support System for allergic rhinitis management: MASK eâ€CDSS. Clinical and Experimental Allergy, 2018, 48, 1640-1653.	2.9	61
47	ARIAâ€EAACI statement on asthma and COVIDâ€19 (June 2, 2020). Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 689-697.	5.7	57
48	Transfer of innovation on allergic rhinitis and asthma multimorbidity in the elderly (<scp>MACVIA</scp>â€<scp>ARIA</scp>) â€•<scp>EIP</scp> on <scp>AHA</scp> Twinning Reference Site (<scp>GARD</scp> research demonstration project). Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 77-92.	5.7	54
49	Adjuvants for immunotherapy. Current Opinion in Allergy and Clinical Immunology, 2012, 12, 648-657.	2.3	52
50	<scp>ARIA</scp> pharmacy 2018 â€œAllergic rhinitis care pathways for community pharmacyâ€• Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 1219-1236.	5.7	52
51	Allergen immunotherapy for allergic rhinoconjunctivitis: a systematic overview of systematic reviews. Clinical and Translational Allergy, 2017, 7, 24.	3.2	49
52	Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5). Clinical and Translational Allergy, 2016, 6, 29.	3.2	47
53	ARIA digital anamorphosis: Digital transformation of health and care in airway diseases from research to practice. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 168-190.	5.7	46
54	Mobile Technology in Allergic Rhinitis: Evolution in Management or Revolution in Health and Care?. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 2511-2523.	3.8	44

#	Article	IF	Citations
55	Maintenance dosing for sublingual immunotherapy by prominent European allergen manufacturers expressed in bioequivalent allergy units. Annals of Allergy, Asthma and Immunology, 2011, 107, 448-458.e3.	1.0	43
56	Pediatric sublingual immunotherapy efficacy: evidence analysis, 2009-2012. Annals of Allergy, Asthma and Immunology, 2013, 110, 402-415.e9.	1.0	43
57	Allergen sensitization linked to climate and age, not to intermittentâ€persistent rhinitis in a crossâ€sectional cohort study in the (sub)tropics. Clinical and Translational Allergy, 2014, 4, 20.	3.2	43
58	Innate and Adaptive Immune Response to Fungal Products and Allergens. Journal of Allergy and Clinical Immunology: in Practice, 2016, 4, 386-395.	3.8	43
59	Sublingual immunotherapy in children: complete and updated review supporting evidence of effect. Current Opinion in Allergy and Clinical Immunology, 2009, 9, 168-176.	2.3	42
60	Real World Biologic Use and Switch Patterns in Severe Asthma: Data from the International Severe Asthma Registry and the US CHRONICLE Study. Journal of Asthma and Allergy, 2022, Volume 15, 63-78.	3.4	41
61	Clinical Evaluation and Management of Patients with Suspected Fungus Sensitivity. Journal of Allergy and Clinical Immunology: in Practice, 2016, 4, 405-414.	3.8	37
62	The Work Productivity and Activity Impairment Allergic Specific (WPAI-AS) Questionnaire Using Mobile Technology: The MASK Study. Journal of Investigational Allergology and Clinical Immunology, 2018, 28, 42-44.	1.3	37
63	CHRODIS criteria applied to the MASK (MACVIA-ARIA Sentinel NetworK) Good Practice in allergic rhinitis: a SUNFRAIL report. Clinical and Translational Allergy, 2017, 7, 37.	3.2	36
64	National clinical practice guidelines for allergen immunotherapy: An international assessment applying <scp>AGREE</scp>â€<scp>II</scp>. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 664-672.	5.7	35
65	Use of omalizumab to improve desensitization safety inÂallergen immunotherapy. Journal of Allergy and Clinical Immunology, 2014, 133, 937-937.e2.	2.9	33
66	Geolocation with respect to personal privacy for the Allergy Diary app - a MASK study. World Allergy Organization Journal, 2018, 11, 15.	3.5	33
67	Enhancing innate immunity against virus in times of COVID-19: Trying to untangle facts from fictions. World Allergy Organization Journal, 2020, 13, 100476.	3.5	33
68	Correlation between work impairment, scores of rhinitis severity and asthma using the MASKâ€air^{Â®} App. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 1672-1688.	5.7	32
69	Development and validation of combined symptomâ€medication scores for allergic rhinitis*. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 2147-2162.	5.7	32
70	Differentiation of COVIDâ€19 signs and symptoms from allergic rhinitis and common cold: An ARIAâ€EAACIâ€GA²LEN consensus. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 2354-2366.	5.7	31
71	Procedures to Assist Health Care Providers to Determine When Home Assessments for Potential Mold Exposure Are Warranted. Journal of Allergy and Clinical Immunology: in Practice, 2016, 4, 417-422.e2.	3.8	29
72	Debates in Allergy Medicine: Allergy skin testing cannot be replaced by molecular diagnosis in the near future. World Allergy Organization Journal, 2017, 10, 32.	3.5	27

#	Article	IF	Citations
73	Update on Omalizumab for Urticaria: Whatâ€™s New in the Literature from Mechanisms to Clinic. Current Allergy and Asthma Reports, 2018, 18, 33.	5.3	27
74	Dosing of European sublingual immunotherapy maintenance solutions relative to monthly recommended dosing of subcutaneous immunotherapy. Allergy and Asthma Proceedings, 2016, 37, 50-56.	2.2	26
75	Evidence of effect of subcutaneous immunotherapy in children: complete and updated review from 2006 onward. Annals of Allergy, Asthma and Immunology, 2011, 107, 407-416.e11.	1.0	25
76	Home Assessment and Remediation. Journal of Allergy and Clinical Immunology: in Practice, 2016, 4, 423-431.e15.	3.8	25
77	Survey on immunotherapy practice patterns: dose, dose adjustments, and duration. Annals of Allergy, Asthma and Immunology, 2012, 108, 373-378.e3.	1.0	22
78	ARIA guideline 2019: treatment of allergic rhinitis in the German health system. Allergo Journal International, 2019, 28, 255-276.	2.0	22
79	One hundred years of immunotherapy: Review of the first landmark studies. Allergy and Asthma Proceedings, 2012, 33, 122-128.	2.2	20
80	Allergy training and immunotherapy in Latin America: results of a regional overview. Annals of Allergy, Asthma and Immunology, 2013, 111, 415-419.e1.	1.0	20
81	Pollen in the atmosphere of Mexico City and its impact on the health of the pediatric population. Atmospheric Environment, 2018, 186, 198-208.	4.1	20
82	Thirtyâ€six COVIDâ€19 cases preventively vaccinated with mumpsâ€measlesâ€rubella vaccine: All mild course. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 910-914.	5.7	20
83	How does the efficacy and safety of Oralair® compare to other products on the market?. Therapeutics and Clinical Risk Management, 2016, 12, 831.	2.0	18
84	Subcutaneous and sublingual immunotherapy in children: Complete update on controversies, dosing, and efficacy. Current Allergy and Asthma Reports, 2008, 8, 465-474.	5.3	17
85	Behavioural patterns in allergic rhinitis medication in Europe: A study using MASKâ€air^{Â®} realâ€world data. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 2699-2711.	5.7	17
86	Skin prick test evaluation of Dermatophagoides pteronyssinus diagnostic extracts from Europe, Mexico, and the United States. Annals of Allergy, Asthma and Immunology, 2010, 104, 420-425.	1.0	16
87	A comparison of in vitro potency between European and Mexican allergen extracts and US (CBER/FDA) reference extracts. Allergologia Et Immunopathologia, 2010, 38, 170-173.	1.7	16
88	European and Mexican vs US diagnostic extracts of Bermuda grass and cat in skin testing. Annals of Allergy, Asthma and Immunology, 2011, 106, 421-428.	1.0	16
89	Chronic urticaria can be caused by cancer and resolves with its cure. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 1562-1566.	5.7	16
90	Certainties and doubts about sublingual and oral immunotherapy in children. Current Opinion in Allergy and Clinical Immunology, 2009, 9, 558-567.	2.3	15

#	Article	IF	Citations
91	Patterns of skin prick test positivity in allergic patients: usefulness of a nationwide SPT chart review. Allergologia Et Immunopathologia, 2011, 39, 330-336.	1.7	15
92	American Academy of Allergy, Asthma & Immunology membership experience with allergen immunotherapy safety in patients with specific medical conditions. Allergy and Asthma Proceedings, 2016, 37, 112-122.	2.2	15
93	Cutaneous Manifestations Related to COVID-19 Immune Dysregulation in the Pediatric Age Group. Current Allergy and Asthma Reports, 2021, 21, 13.	5.3	15
94	Allergen immunotherapy for allergic rhinoconjunctivitis: protocol for a systematic review. Clinical and Translational Allergy, 2016, 6, 12.	3.2	14
95	The Role of Mobile Health Technologies in Stratifying Patients for AIT and Its Cessation: The ARIA-EAACI Perspective. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 1805-1812.	3.8	14
96	Allergen immunotherapy for the prevention of allergic disease: protocol for a systematic review. Pediatric Allergy and Immunology, 2016, 27, 236-241.	2.6	13
97	Physicians' experience and opinion on contraindications to allergen immunotherapy: The CONSIT survey. Annals of Allergy, Asthma and Immunology, 2017, 118, 621-628.e1.	1.0	13
98	American Academy of Asthma, Allergy & Immunology membership experience with venom immunotherapy in chronic medical conditions and pregnancy, and in young children. Allergy and Asthma Proceedings, 2017, 38, 121-129.	2.2	13
99	Coronavirus disease 2019, allergic diseases, and allergen immunotherapy: Possible favorable mechanisms of interaction. Allergy and Asthma Proceedings, 2021, 42, 187-197.	2.2	13
100	Food allergen sensitization patterns in a large allergic population in Mexico. Allergologia Et Immunopathologia, 2020, 48, 553-559.	1.7	13
101	Impact of Socioeconomic Status on Adult Patients with Asthma: A Population-Based Cohort Study from UK Primary Care. Journal of Asthma and Allergy, 2021, Volume 14, 1375-1388.	3.4	13
102	Over Diagnosis of Persistent Allergic Rhinitis in Perennial Allergic Rhinitis Patients: A Nationwide Study in Mexico. American Journal of Rhinology and Allergy, 2013, 27, 495-501.	2.0	12
103	Gaps in allergen immunotherapy administration and subcutaneous allergen immunotherapy dose adjustment schedules. Annals of Allergy, Asthma and Immunology, 2020, 125, 505-506.e2.	1.0	12
104	Sublingual immunotherapy: Dosing in relation to clinical and immunological efficacy. Allergy and Asthma Proceedings, 2008, 29, 130-139.	2.2	11
105	What you should not miss from the systematic reviews and meta-analyses on allergen-specific immunotherapy in 2017. Current Opinion in Allergy and Clinical Immunology, 2018, 18, 168-176.	2.3	11
106	Anxiety and depression in adult patients with asthma: the role of asthma control, obesity and allergic sensitization. Journal of Asthma, 2021, 58, 1058-1066.	1.7	11
107	In the (Sub)Tropics Allergic Rhinitis and Its Impact on Asthma Classification of Allergic Rhinitis is More Useful than Perennialâ€“Seasonal Classification. American Journal of Rhinology and Allergy, 2014, 28, 232-238.	2.0	10
108	Coronavirus disease 2019 and allergen immunotherapy. Annals of Allergy, Asthma and Immunology, 2020, 125, 247-249.	1.0	10

#	Article	IF	Citations
109	Oralair Birch, a recombinant major birch pollen allergen tablet for sublingual immunotherapy of allergic rhinitis caused by birch pollen. Current Opinion in Investigational Drugs, 2010, 11, 586-96.	2.3	10
110	Allergen immunotherapy. Current Opinion in Allergy and Clinical Immunology, 2015, 15, 556-567.	2.3	9
111	Intranasal Corticosteroids: Topical Potency, Systemic Activity and Therapeutic Index. Journal of Asthma and Allergy, 2021, Volume 14, 1093-1104.	3.4	9
112	Prevalence and triggers of self-reported nasal hyperreactivity in adults with asthma. World Allergy Organization Journal, 2020, 13, 100132.	3.5	9
113	Allergen immunotherapy in MASKâ€air users in realâ€life: Results of a Bayesian mixedâ€effects model. Clinical and Translational Allergy, 2022, 12, e12128.	3.2	9
114	Patient-reported outcomes and quality-of-life questionnaires in the assessment of rhinoconjunctivitis in childhood. Current Opinion in Allergy and Clinical Immunology, 2014, 14, 192-199.	2.3	8
115	Direct comparison of efficacy of sublingual immunotherapy tablets for rhinoconjunctivitis. Annals of Allergy, Asthma and Immunology, 2016, 116, 274-286.	1.0	8
116	Risk factors for wheezing in primary health care settings in the tropics. Annals of Allergy, Asthma and Immunology, 2020, 124, 179-184.e1.	1.0	8
117	Beyond eosinophilia: inflammatory patterns in patients with asthma. Journal of Asthma, 2022, 59, 255-263.	1.7	8
118	Comparison of rhinitis treatments using <scp>MASK</scp>â€airÂ® data and considering the minimal important difference. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 3002-3014.	5.7	8
119	Similar biological activity in skin prick test for Oralair^{Â®} (8200 <scp>BAU</scp>) and Grazax^{Â®} (6200 <scp>BAU</scp>) reinforces effective SLIT dosing level. Allergy: European Journal of Allergy and Clinical Immunology, 2016, 71, 1782-1786.	5.7	7
120	Moving toward consensus on diagnosis and management of severe asthma in children. Current Medical Research and Opinion, 2018, 34, 447-458.	1.9	7
121	Consensus on mild asthma management: results of a modified Delphi study. Journal of Asthma, 2023, 60, 145-157.	1.7	7
122	The characterization of asthma with blood eosinophilia in adults in Latin America. Journal of Asthma, 2019, 56, 1138-1146.	1.7	6
123	Long-term adherence strategies for allergen immunotherapy. Allergy and Asthma Proceedings, 2022, 43, 299-304.	2.2	6
124	Sublingual immunotherapy in children: more optimism today. Pediatric Allergy and Immunology, 2009, 20, 399-400.	2.6	5
125	Will Sublingual Immunotherapy Offer Benefit for Asthma?. Current Allergy and Asthma Reports, 2013, 13, 571-579.	5.3	5
126	Very rarely chronic urticaria can be caused by cancer and if so, resolves with its cure. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 1925-1926.	5.7	5

#	Article	IF	Citations
127	Compromising between European and US allergen immunotherapy schools: Discussions from GUIMIT, the Mexican immunotherapy guidelines. World Allergy Organization Journal, 2020, 13, 100444.	3.5	5
128	Food and Drug Administration reclassification of allergens for diagnosis and treatment: now is the time to be heard. Annals of Allergy, Asthma and Immunology, 2012, 109, 6-9.	1.0	4
129	Patient selection for subcutaneous versus sublingual immunotherapy. Current Opinion in Allergy and Clinical Immunology, 2015, 15, 588-595.	2.3	4
130	Pediatric asthma treatment. Annals of Allergy, Asthma and Immunology, 2018, 121, 7-13.e4.	1.0	4
131	Acute emotional stress proposed as a risk factor for anaphylaxis in patients receiving allergen immunotherapy. Annals of Allergy, Asthma and Immunology, 2020, 124, 314-317.	1.0	4
132	An independent inâ€depth analysis proposing adjusted Global Initiative on Asthma Step 1â€“2 treatment suggestions. Clinical and Experimental Allergy, 2022, 52, 493-511.	2.9	3
133	Leukotriene Receptor Antagonists and the Risk of Neuropsychiatric Disease: Could There Be a Genetic Predisposition?. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 4298-4299.	3.8	3
134	Briefings from ACAAI 2008 Annual meeting. Therapy: Open Access in Clinical Medicine, 2009, 6, 279-283.	0.2	1
135	Author response. Annals of Allergy, Asthma and Immunology, 2013, 111, 306-307.	1.0	1
136	Worldwide allergen immunotherapy guidelines: Evidence and experience-based. Allergologia Et Immunopathologia, 2017, 45, 17-22.	1.7	1
137	Perceptions and Management of Allergic Rhinitis Among Ecuadorian Otorhinolaryngologists: A Survey-Based Study . Journal of Multidisciplinary Healthcare, 2020, Volume 13, 1975-1981.	2.7	1
138	House dust mite liquid SLIT effective in atopic dermatitis even with suboptimal dosing. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 1936-1937.	3.8	1
139	Allergic Sensitization and Rhinitis in Children: What Is New?. Current Treatment Options in Allergy, 2015, 2, 20-31.	2.2	0
140	Allergen immunotherapy is safe during pollen season. Results of a 10-year, real-life prospective study. Revue Francaise D'allergologie, 2017, 57, 302-307.	0.2	0
141	Author response. Annals of Allergy, Asthma and Immunology, 2020, 125, 116.	1.0	0
142	CME suggestions for pediatricians, allergists, and dermatologists, directed by an online survey on urticaria knowledge. Allergologia Et Immunopathologia, 2021, 49, 87-94.	1.7	0
143	Comparing Antihistamines in Chronic Spontaneous Urticaria: Possible Future Directions. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 2272-2273.	3.8	0